The combination of neurodegenerative and vascular mechanisms in the pathway of old age dementia
https://doi.org/10.30629/2618-6667-2017-76-97-107
Abstract
The aim of the study is to analyze literature data about the possibility of the combination of neurodegenerative and vascular mechanisms in the development of old age dementia. Material and method: this review describes the analysis of the literature on the participation of neurodegenerative and vascular mechanisms in the development of dementia. The literature review concerned the assessment of its pathogenic mechanisms and the possible relationship between these processes. It was analyzed the modern approaches to pharmacological correction of these disorders, including the range of biochemical activity and mechanisms of action of the main directions of therapy of dementia. Conclusion: the analysis of literary data demonstrates the commonality of risk factors, the presence of intersecting pathogenetic processes and the possibility of the additive and synergistic interaction of vascular and atrophic brain processes.
About the Authors
Elena Ponomareva
FSBSI «Mental Health Research Centre», Moscow
Russian Federation
PhD, MD, candidate of medical sciences, senior researcher
Russian Federation
PhD, MD, candidate of medical sciences, senior researcher
Evgenia Teleshova
Research-Practical Psychoneurological Center, Moscow; FSBI «Zakusov Institute of Pharmacology», Moscow
Russian Federation
PhD, MD, candidate of medical sciences, psychiatrist, senior researcher
Russian Federation
PhD, MD, candidate of medical sciences, psychiatrist, senior researcher
Timur Syunyakov
FSBI «Zakusov Institute of Pharmacology», Moscow; Pfizer LLC, Moscow
Russian Federation
Russian Federation
PhD, MD, candidate of medical sciences, senior researcher, medical advisor
References
1. Abbott A. Dementia: a problem for our age. Nature. 2011;475(7355):2–4. doi.org/10.1038/475s2a
2. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., Dodel R., Ekman M., Faravelli C., Fratiglioni L., Gannon B., Hilton Jones D., Jennum P., Jordanova A., Jönsson L., Karampampa K., Knapp M., Kobelt G., Kurth T., Lieb R., Linde M., Ljungcrantz C., Maercker A., Melin B., Moscarelli M., Musayev A., Norwood F., Preisig M., Pugliatti M., Rehm J., Carulla L.-S., Schlehofer B., Simon R., Steinhausen H.-C., Stovner L.J., Vallat J.-M., Bergh P., Os J., Vos P., Xu W., Wittchen H.-U., Jönsson B., Olesen J. Cost of disorders of the brain in Europe. Eur. Neuropsy- chopharmacol. 2011; 21(10): 718–779. https://doi.org/10.1016/j. euroneuro.2012.01.001
3. Olesen J., Gustavsson A., Svensson M., Wittchen H.-U., Jönsson B. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012;19(1):155–162. doi.org/10.1111/j.1468-1331.2011.03590.x
4. Jessen F. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers. Dement. 2013; 9(4): 824. doi: http://dx.doi.org/10.1016/j.jalz.2013.04.451
5. Gavrilova S.I., Vol'pina O.M., Kolykhalov I.V., Fedorova Ya.B., Selezneva N.D., Ponomareva E.V., Koroev D.O., Kamynina A.V. Terapevticheskii monitoring i prognoz effektivnosti neirotroficheskoi terapii u patsientov s sindromom myagkogo kognitivnogo snizheniya amnesticheskogo tipa. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;8:27–38. (In Russ.).
6. Gavrilova S.I. Approaches to preventive treatment of Alzheimer’s disease: problems and possibilities. Psychhiatry. 2014;1:5-12. (In Russ.).
7. Gavrilova S.I., Kolykhalov I.V., Fedorova Ya.B., Kalyn Ya.B., Selezneva N.D., Samorodov A.V., Myasoedov S.N., Boksha I.S. Prognoz progressirovaniya kognitivnogo defitsta u pozhilykh patsientov s sindromom myagkogo kognitivnogo snizheniya pri dlitel'nom lechenii (3-letnee nablyudenie). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;3(1):45–53. (In Russ.).
8. Molochkina E. M., Fatkullina L. D., Podchufarova D. E., Goloshchapov A.N., Gavrilova S.I., Fedorova Ya.B., Klyushnik T.P., Burlakova E.B. Features of structural and functional status of erythrocyte membranes in the syndrome of mild cognitive impairment. Psychiatry. 2014;1:21–26. (In Russ.).
9. Edmonds E.C., Delano-Wood L., Galasko D.R., Salmon D.P., Bondi M.W. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J. Int. Neuropsychol. Soc. NIH Public Access 2014;20(8):836–847. https://doi.org/10.1017/ s135561771400068x
10. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J.,. Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1–2):125–132. https://doi.org/10.1159/000109998
11. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: How to move forward? Neurology. 2009;72(4):368–374. http://dx.doi.org/10.1212/01.wnl.0000341271.90478.8e
12. Kalaria R.N., Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer disease and Associated disorders. 1999;13(3):115–123. doi: 10.1097/00002093-199912003-00017
13. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901– 2908. doi:10.1001/jama.292.23.2901
14. Rukovodstvo po geriatricheskoi psikhiatrii. Pod red. S.I. Gavrilovoi. M.: Pul's. 2011:113–129. ISBN 978-5-93486-065-4. (In Russ.).
15. Gavrilova S.I., Kalyn Ya.B. Sotsial'nye faktory i psikhicheskie rasstroistva v pozhilom i starcheskom vozraste. V kn.: Rukovodstvo po sotsial'noi psikhiatrii. Pod red. T.B. Dmitrievoi. M. «Meditsina»; 2001:136-161. (In Russ).
16. Mikhailova N.M. Diagnostika i terapiya smeshannoi (al'tsgeimerovsko-sosudistoi) dementsii. Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;3:18–26. (In Russ.).
17. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69: 2197–2204. doi: http://dx.doi.org/10.1212/01.wnl.0000271090.28148.24
18. Levin O.S. Diagnostika i lechenie dementsii v klinicheskoi praktike. M.: «Medpress-inform»; 2010:255. (In Russ).
19. Mikhailova N.M., Roshchina I.F. Mixed Dementia. Part 1. The Clinical and Neuropsychological Aspects. Psychiatry. 2012;53– 55(1–3):24–37. (In Russ.).
20. Mikhailova N.M., Bozhko O.V. Mixed Dementia. Part 2. Psychiatry. 2012;53–55(1– 3):38–58. (In Russ.).
21. Jellinger K.A., Attems J. Incidence of cerebrovascular lesions in Alzheimer’s disease: a postmortem study. Acta Neuropathol. 2003;105(1):14–17.
22. Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer’s disease Nat. Publ. Gr. 2015;1:15056. https://doi.org/10.1038/nrdp.2015.56
23. Silvestre J.-S., Smadja D.M., Levy B.I. Postischemicrevascularization: rom cellular and molecular mechanisms to clinical applications. Physiol. Rev. 2013;93(4):1743–1802. https://doi.org/10.1152/physrev.00006.2013
24. Zaleska M.M., Mercado M.L.T., Chavez J., Feuerstein G.Z., Pangalos M.N., Wood A. The development of stroke therapeutics: Promising mechanisms and translational challenges. Neuropharmacology. Elsevier Ltd, 2009;56(2):329–341. https://doi.org/10.1016/j.neuropharm.2008.10.006
25. Gorelick P.B. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(11):2620–2622. https://doi.org/10.1161/01.str.0000143318.70292.47
26. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience. 2011;12:723–738. doi:10.1038/nrn3114
27. Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer's disease. Nature Neuroscience. 2015;16(6):358–372. https://doi.org/10.1038/nrn3880
28. Mandrekar-Colucci S. , Landreth G. E. Microglia and inflammation in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. NIH Public Access. 2010;9(2):156–167. https://doi.org/10.2174/187152710791012071
29. Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer’s disease — lessons from pathology. BMC Medicine. 2014;12(1). https://doi.org/10.1186/s12916-014-0206-2
30. Olichney J.M. et al. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1997;826(127):493–497. https://doi.org/10.1186/s12916-014-0206-2
31. Xu M., Zhang H. Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol. Sin. 2011;32:1089–1099. https://doi.org/10.1038/aps.2011.50
32. Cai Z., Xiao M. Oligodendrocytes and Alzheimer's disease. Int. J. Neurosci. 2016;126(2):97–104. doi: 10.3109/00207454.2015.1025778
33. Esposito Z., Belli L., Toniolo S., Sancesario G., Bianconi C., Martorana A. Amyloid β, glutamate, excitotoxicity in Alzheimer’s disease: Are we on the right track? CNS Neurosci. Ther. 2013;19(8):549–555. https://doi.org/10.1111/cns.12095
34. Sorbera L.A., Bozzo J., Serradell N. Alzheimer’s disease one century later: The search for effective therapeutic targets continues. Drugs Future. 2007;32(7):625. https://doi.org/10.1358/dof.2007.032.07.1116862
35. Wang J., Zhang H.-Y., Tang X.-C. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol. Sin. 2009;30(30):879–888. https://doi.org/10.1038/aps.2009.82
36. Bekker P.A., Bykov Yu.V. Memantin: vozmozhnosti i perspektivy primeneniya v psikhiatrii (obzor sovremennykh dannykh). Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2016;4:42–51. (In Russ.).
37. Asai S., Zhao H., Yamashita A., Jike T., Kunimatsu T., Nagata T., Kohno T., Ishikawa K. Nicergoline enhances glutamate re-uptake and protects against brain damage in rat global brain ischemia. Eur. J. Pharmacol. 1999;383(3):267–274. https://doi.org/10.1016/s0014-2999(99)00623-8
38. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Chandrasekhar Rao Venkata Damaraju. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;(359):1283–1290. https://doi.org/10.1016/s0140-6736(02)08267-3
39. Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;(7):159–169. https://doi.org/10.1046/j.1468-1331.2000.00046.x
40. Orgogozo J.M., Rigaud A.S., Stoffler A. et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834–1839. https://doi.org/10.1161/01. str.0000020094.08790.49
41. Gavrilova S.I., Kolykhalov I.V., Selezneva N.D., Zharikov G.A. i dr. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie vliyaniya tserebrolizina na effektivnost' i perenosimost'posleduyushchei kholinergicheskoi terapii u bol'nykh s bolezn'yu Al'tsgeimera. Sotsial'naia i klinich. psikhiatria. 2000;2:41–46. (In Russ.).
42. Gerasimov N.P. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie effektivnosti tserebrolizina pri bolezni Al'tsgeimera. Sotsial'naya i klinicheskaya psikhiatriya. 2000;2:35–40. (In Russ.).
43. Alvarez X.A., Cacabelos R., Sampedro C., Couceiro V., Aleixandre M., Vargas M., Linares C., Granizo E., García-Fantini M., Baurecht W., Doppler E., Moessler H. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr. Alzheimer. Res. 2011;8(5):583– 591. https://doi.org/10.2174/156720511796391863
44. Gauthier S., Proano J.V., Jia J., Froelich L., Vester J.C., Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Alzheimer’s and Dementia. 2014;10(4):859. https://doi.org/10.1016/j.jalz.2014.05.1709
45. Nishida A., Iwata H., Kudo Y., Kobayashi T., Matsuoka Y., Kanai Y., Endou H. Nicergoline enhances glutamate uptake via glutamate transporters in rat cortical synaptosomes. Biol. Pharm. Bull. 2004;27(6):817–820. https://doi.org/10.1248/bpb.27.817
46. Battaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 1989;37(4):295–302. doi: 10.1111/j.15325415.1989.tb05494.x
47. Nappi G., Bono G., Merlo P., Borromei A., Caltagirone C., Lomeo C., Martucci N., Fabbrini G., Annoni K., Battaglia A. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multi-centre, double-blind, placebocontrolled study. Clin. Drug Invest. 1997;13(6):308–316. doi: 10.2165/00044011-199713060-00003
48. Radzivil G.G., Gerasimov N.P., Selezneva N.D., Krasnoperova M.G. Sostoyanie tsentral'noi gemodinamiki u bol'nykh s dementsiei al'tsgeimerovskogo tipa v protsesse terapii nitsergolinom. V kn. Bolezn' Al'tsgeimera i starenie: ot neirobiologii k terapii. Moskva. 1999;112–114. (In Russ.).
49. Ponomareva E.V. The use of Sermion in the complex therapy of outpatients with old age dementia. Psychiatry. 2017;73(1):49–59. (In Russ.).
50. Winblad B., Carfagna N., Bonura L., Rossini B.M., Wong E.H.F., Battaglia A. Nicergoline in Dementia. CNS Drugs. Springer International Publishing. 2000;14(4):267–287. https://doi.org/10.2165/00023210-200014040-00003
51. Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews / ed. Fioravanti M. Chichester, UK: John Wiley & Sons, Ltd. 2001;4:CD003159. https://doi.org/10.1002/14651858.cd003159
52. Matsuoka Y., Fukushima T., Iwata H., Matsumoto M., Shibutani Y., Kwashima K., Kudo Y., Ishida R. Inhibitory action of nicergoline and its metabolites on acetylcholinesterase activity in rats and mouse brain. Adv. Behav. Biol. 1990;38:415–419. https://doi.org/10.1007/978-1-4684-5847-3_84
53. Ponomareva E.V. The use of nicergoline in gerontological practice. Psychiatry. 2016;3(71):106–120. (In Russ.).
54. Aguero-Torres H., Kivipelto M., von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen Project. Dement. Geriatr. Cogn. Disord. 2006;22(3):244–249. doi: 10.1159/000094973
55. Lobzin V.Yu. Kompleksnaya rannyaya diagnostika narushenii kognitivnykh funktsii. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(11):72–79. (In Russ.).
56. Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 2006;100(1):328–335. doi: 10.1152/japplphysiol.00966.2005
57. Roman G.C., Kalaria R.N. Vascular determinants of cholinergic deficits in Alzheimer's disease and vascular dementia. Neurobiol. Aging. 2006;27(12):1769–1785. doi: http://dx.doi.org/10.1016/j.neurobiolaging.2005.10.004
58. Santos C.Y., Snyder P. J., Wu W.-Ch., Zhang M., Echeverria A., Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement. (Amst). 2017;7:69–87. Published online 2017 Feb 9. doi: 10.1016/j.dadm.2017.01.005
59. Ji F., Pasternak O., Liu S., Loke Y.M., Choo B.L., Hilal S., Xu X., Ikram M.K., Venketasubramanian N., Chen C.L.-H., Zhou J. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease. Alzheimers Res. Ther. 2017;9:63. Published online 2017 Aug 17. doi: 10.1186/ s13195-017-0292-4
60. Raz L., Knoefel J., Bhaskar K. The neuropathology and cerebro- vascular mechanisms of dementia. J. Cereb. Blood Flow Metab. 2016Jan;36(1):172–186. doi: 10.1038/jcbfm.2015.164.
Review
For citations:
Ponomareva E., Teleshova E., Syunyakov T. The combination of neurodegenerative and vascular mechanisms in the pathway of old age dementia. Psychiatry (Moscow) (Psikhiatriya). 2017;(76):97-107. (In Russ.) https://doi.org/10.30629/2618-6667-2017-76-97-107
Views:
924
Email this article 
